Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Caveolin 1 | 12 | 2020 | 263 | 3.940 |
Why?
|
| Receptors, Mineralocorticoid | 14 | 2023 | 164 | 2.670 |
Why?
|
| Aldosterone | 25 | 2023 | 877 | 2.370 |
Why?
|
| Sodium, Dietary | 11 | 2023 | 418 | 1.730 |
Why?
|
| Sodium Chloride, Dietary | 12 | 2023 | 281 | 1.360 |
Why?
|
| Hypertension | 25 | 2023 | 8480 | 1.250 |
Why?
|
| Angiotensin II | 10 | 2023 | 881 | 1.180 |
Why?
|
| Vasoconstriction | 6 | 2015 | 597 | 1.160 |
Why?
|
| Histone Demethylases | 7 | 2022 | 321 | 1.120 |
Why?
|
| Blood Pressure | 25 | 2023 | 8554 | 1.080 |
Why?
|
| Calmodulin-Binding Proteins | 6 | 2020 | 249 | 0.980 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2013 | 1504 | 0.970 |
Why?
|
| Spironolactone | 7 | 2020 | 382 | 0.820 |
Why?
|
| Nitric Oxide Synthase Type III | 5 | 2013 | 689 | 0.790 |
Why?
|
| Renin-Angiotensin System | 9 | 2019 | 759 | 0.710 |
Why?
|
| Renin | 7 | 2017 | 642 | 0.710 |
Why?
|
| Zona Glomerulosa | 5 | 2021 | 86 | 0.690 |
Why?
|
| Insulin Resistance | 7 | 2018 | 3864 | 0.650 |
Why?
|
| Caloric Restriction | 2 | 2018 | 302 | 0.650 |
Why?
|
| Dinucleoside Phosphates | 3 | 2004 | 74 | 0.630 |
Why?
|
| Aorta | 8 | 2015 | 2061 | 0.610 |
Why?
|
| Oxidoreductases, N-Demethylating | 3 | 2012 | 115 | 0.590 |
Why?
|
| Nitric Oxide | 4 | 2015 | 2132 | 0.560 |
Why?
|
| Cyclic GMP | 3 | 2015 | 409 | 0.510 |
Why?
|
| Vasodilation | 3 | 2015 | 944 | 0.510 |
Why?
|
| Signal Transduction | 17 | 2020 | 23403 | 0.500 |
Why?
|
| Mice, Knockout | 15 | 2022 | 14557 | 0.470 |
Why?
|
| Endothelium, Vascular | 7 | 2013 | 4456 | 0.470 |
Why?
|
| NG-Nitroarginine Methyl Ester | 6 | 2023 | 255 | 0.440 |
Why?
|
| Muscle Relaxation | 2 | 2010 | 142 | 0.430 |
Why?
|
| Nerve Tissue Proteins | 6 | 2020 | 4462 | 0.430 |
Why?
|
| Fumarates | 1 | 2012 | 132 | 0.410 |
Why?
|
| Kidney Diseases | 1 | 2023 | 2149 | 0.400 |
Why?
|
| Cardiovascular System | 2 | 2015 | 832 | 0.380 |
Why?
|
| Adenosine Triphosphate | 4 | 2004 | 2025 | 0.360 |
Why?
|
| Amides | 1 | 2012 | 459 | 0.350 |
Why?
|
| Blood Glucose | 4 | 2018 | 6256 | 0.330 |
Why?
|
| Membrane Proteins | 6 | 2020 | 7880 | 0.330 |
Why?
|
| Kidney | 9 | 2023 | 7186 | 0.310 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 1889 | 0.310 |
Why?
|
| Animals | 43 | 2023 | 168757 | 0.300 |
Why?
|
| Epoprostenol | 3 | 2004 | 254 | 0.300 |
Why?
|
| Mice | 23 | 2023 | 81183 | 0.300 |
Why?
|
| Adrenal Glands | 3 | 2020 | 546 | 0.290 |
Why?
|
| Nitric Oxide Synthase | 1 | 2010 | 916 | 0.290 |
Why?
|
| Cardiomegaly | 1 | 2010 | 620 | 0.290 |
Why?
|
| Rats, Wistar | 9 | 2023 | 1901 | 0.280 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2006 | 202 | 0.260 |
Why?
|
| Vasoconstrictor Agents | 5 | 2015 | 642 | 0.260 |
Why?
|
| Luciferases | 2 | 2004 | 733 | 0.260 |
Why?
|
| Diet, Sodium-Restricted | 3 | 2017 | 287 | 0.250 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1373 | 0.250 |
Why?
|
| Glucose | 1 | 2016 | 4397 | 0.240 |
Why?
|
| Adenine Nucleotides | 1 | 2004 | 121 | 0.240 |
Why?
|
| Homeostasis | 4 | 2020 | 3340 | 0.230 |
Why?
|
| Antihypertensive Agents | 2 | 2013 | 2046 | 0.230 |
Why?
|
| Resistin | 2 | 2016 | 170 | 0.230 |
Why?
|
| Albuminuria | 3 | 2023 | 682 | 0.210 |
Why?
|
| Vasodilator Agents | 4 | 2011 | 977 | 0.200 |
Why?
|
| Guanylate Cyclase | 2 | 2013 | 201 | 0.200 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3255 | 0.200 |
Why?
|
| Dyslipidemias | 2 | 2020 | 849 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2023 | 15519 | 0.180 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2011 | 152 | 0.180 |
Why?
|
| Citrulline | 1 | 2000 | 105 | 0.180 |
Why?
|
| Male | 40 | 2023 | 350118 | 0.180 |
Why?
|
| Cytosol | 1 | 2003 | 901 | 0.180 |
Why?
|
| Aminopeptidases | 1 | 2019 | 88 | 0.170 |
Why?
|
| Insulin | 5 | 2017 | 6580 | 0.170 |
Why?
|
| Myocardium | 4 | 2020 | 4776 | 0.170 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2019 | 298 | 0.160 |
Why?
|
| Genetic Variation | 2 | 2011 | 6544 | 0.160 |
Why?
|
| Cardiovascular Diseases | 4 | 2019 | 15165 | 0.150 |
Why?
|
| Zona Reticularis | 1 | 2017 | 8 | 0.150 |
Why?
|
| Cattle | 5 | 2004 | 3922 | 0.150 |
Why?
|
| Aldehyde Reductase | 1 | 2016 | 65 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2023 | 13033 | 0.140 |
Why?
|
| Estrogen Receptor beta | 1 | 2017 | 175 | 0.140 |
Why?
|
| Triglycerides | 2 | 2016 | 2454 | 0.140 |
Why?
|
| Gene Frequency | 4 | 2016 | 3588 | 0.140 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2016 | 93 | 0.140 |
Why?
|
| Arginine | 1 | 2000 | 944 | 0.140 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 3647 | 0.130 |
Why?
|
| Potassium | 1 | 2020 | 1336 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 4751 | 0.130 |
Why?
|
| Calcium | 3 | 2003 | 5756 | 0.130 |
Why?
|
| Sex Factors | 5 | 2020 | 10397 | 0.130 |
Why?
|
| Genotype | 6 | 2015 | 12951 | 0.130 |
Why?
|
| Blotting, Western | 3 | 2014 | 5179 | 0.120 |
Why?
|
| Captopril | 2 | 2013 | 272 | 0.120 |
Why?
|
| Cholesterol | 3 | 2020 | 2917 | 0.120 |
Why?
|
| Phenylephrine | 2 | 2015 | 301 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 5 | 2023 | 21827 | 0.120 |
Why?
|
| Caveolins | 1 | 2014 | 104 | 0.120 |
Why?
|
| Enzyme Inhibitors | 3 | 2015 | 3798 | 0.120 |
Why?
|
| Heart Injuries | 1 | 2015 | 210 | 0.110 |
Why?
|
| Hypertriglyceridemia | 1 | 2016 | 293 | 0.110 |
Why?
|
| Cells, Cultured | 6 | 2021 | 19229 | 0.110 |
Why?
|
| Heart | 2 | 2019 | 4467 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 638 | 0.100 |
Why?
|
| Rats | 8 | 2023 | 24260 | 0.100 |
Why?
|
| Estrogens | 2 | 2022 | 1566 | 0.100 |
Why?
|
| Alleles | 3 | 2020 | 6933 | 0.100 |
Why?
|
| Phenotype | 6 | 2014 | 16365 | 0.100 |
Why?
|
| Endothelial Cells | 3 | 2011 | 3479 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 2015 | 913 | 0.100 |
Why?
|
| Luminescent Measurements | 2 | 2004 | 405 | 0.100 |
Why?
|
| Hydroxycholecalciferols | 1 | 2011 | 44 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2021 | 2585 | 0.100 |
Why?
|
| Receptors, Purinergic P2 | 2 | 2004 | 153 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2013 | 10943 | 0.090 |
Why?
|
| Obesity | 1 | 2013 | 12745 | 0.090 |
Why?
|
| Binding, Competitive | 2 | 2004 | 1157 | 0.090 |
Why?
|
| Nucleotides | 2 | 2023 | 464 | 0.090 |
Why?
|
| Angiotensinogen | 1 | 2011 | 163 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 611 | 0.090 |
Why?
|
| Calcifediol | 1 | 2011 | 166 | 0.090 |
Why?
|
| Adiponectin | 2 | 2017 | 1100 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 2109 | 0.090 |
Why?
|
| Glucose Tolerance Test | 1 | 2012 | 1150 | 0.090 |
Why?
|
| Disease Models, Animal | 5 | 2018 | 18029 | 0.080 |
Why?
|
| Acetylcholine | 1 | 2010 | 621 | 0.080 |
Why?
|
| Models, Biological | 2 | 2011 | 9583 | 0.080 |
Why?
|
| Substrate Specificity | 2 | 2004 | 1801 | 0.080 |
Why?
|
| Random Allocation | 1 | 2012 | 2429 | 0.080 |
Why?
|
| Isometric Contraction | 1 | 2008 | 143 | 0.080 |
Why?
|
| Haplotypes | 2 | 2011 | 2779 | 0.080 |
Why?
|
| PPAR gamma | 1 | 2010 | 493 | 0.070 |
Why?
|
| Receptors, Cell Surface | 2 | 2011 | 2866 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2013 | 1801 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2019 | 8436 | 0.070 |
Why?
|
| Models, Animal | 2 | 2011 | 2171 | 0.070 |
Why?
|
| Adipose Tissue | 2 | 2016 | 3279 | 0.070 |
Why?
|
| Metformin | 1 | 2013 | 835 | 0.070 |
Why?
|
| Aorta, Thoracic | 2 | 2011 | 1082 | 0.070 |
Why?
|
| Xanthenes | 2 | 2003 | 73 | 0.070 |
Why?
|
| Female | 20 | 2023 | 380194 | 0.070 |
Why?
|
| Sodium | 2 | 2023 | 1623 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2013 | 1990 | 0.070 |
Why?
|
| Models, Molecular | 1 | 2015 | 5456 | 0.060 |
Why?
|
| Fasting | 1 | 2011 | 1593 | 0.060 |
Why?
|
| Middle Aged | 14 | 2019 | 213383 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2011 | 2634 | 0.060 |
Why?
|
| Hemodynamics | 2 | 2014 | 4199 | 0.060 |
Why?
|
| Chromatography, Thin Layer | 1 | 2004 | 223 | 0.060 |
Why?
|
| Humans | 27 | 2023 | 744343 | 0.060 |
Why?
|
| Adult | 13 | 2019 | 214055 | 0.060 |
Why?
|
| Tritium | 1 | 2004 | 745 | 0.060 |
Why?
|
| Calcium Channel Blockers | 2 | 1997 | 690 | 0.060 |
Why?
|
| Autoradiography | 1 | 2004 | 745 | 0.060 |
Why?
|
| Bradykinin | 1 | 2003 | 214 | 0.050 |
Why?
|
| Body Weight | 2 | 2008 | 4669 | 0.050 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 4328 | 0.050 |
Why?
|
| Arteriosclerosis | 2 | 1997 | 1092 | 0.050 |
Why?
|
| Secretory Pathway | 1 | 2021 | 51 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 2872 | 0.050 |
Why?
|
| Systole | 2 | 2006 | 958 | 0.050 |
Why?
|
| Aniline Compounds | 2 | 2003 | 986 | 0.050 |
Why?
|
| Pravastatin | 1 | 2023 | 395 | 0.050 |
Why?
|
| Liver | 1 | 2016 | 7474 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2023 | 625 | 0.050 |
Why?
|
| Fluorescence | 1 | 2003 | 751 | 0.050 |
Why?
|
| Suramin | 1 | 2000 | 34 | 0.050 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 865 | 0.050 |
Why?
|
| Simvastatin | 1 | 2023 | 360 | 0.050 |
Why?
|
| Stroke | 1 | 2023 | 9981 | 0.050 |
Why?
|
| Risk Factors | 5 | 2019 | 72290 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2006 | 1116 | 0.040 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 2703 | 0.040 |
Why?
|
| Diltiazem | 2 | 1997 | 133 | 0.040 |
Why?
|
| Diabetic Nephropathies | 1 | 2006 | 984 | 0.040 |
Why?
|
| Pulse | 1 | 1998 | 229 | 0.040 |
Why?
|
| Animal Nutritional Physiological Phenomena | 1 | 2017 | 57 | 0.040 |
Why?
|
| Fluorescent Dyes | 2 | 2003 | 1917 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 13815 | 0.040 |
Why?
|
| Sulfones | 1 | 2020 | 437 | 0.040 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2017 | 86 | 0.040 |
Why?
|
| Lysine | 1 | 2022 | 1007 | 0.040 |
Why?
|
| Mutation | 2 | 2020 | 29786 | 0.040 |
Why?
|
| Age Factors | 3 | 2019 | 18370 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 18111 | 0.040 |
Why?
|
| Adolescent | 3 | 2017 | 85781 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 17446 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 12072 | 0.030 |
Why?
|
| Corticosterone | 1 | 2017 | 310 | 0.030 |
Why?
|
| Aged | 6 | 2017 | 163280 | 0.030 |
Why?
|
| Diastole | 1 | 1998 | 791 | 0.030 |
Why?
|
| Nifedipine | 1 | 1996 | 226 | 0.030 |
Why?
|
| Young Adult | 3 | 2017 | 56430 | 0.030 |
Why?
|
| Biological Transport | 1 | 2000 | 2118 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 302 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2014 | 2645 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 1423 | 0.030 |
Why?
|
| NAD | 1 | 2017 | 593 | 0.030 |
Why?
|
| Pyrroles | 1 | 2020 | 1146 | 0.030 |
Why?
|
| Aging | 1 | 2012 | 8664 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2011 | 12720 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2015 | 40561 | 0.030 |
Why?
|
| Caveolin 3 | 1 | 2011 | 25 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1998 | 3508 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2006 | 3336 | 0.030 |
Why?
|
| Body Height | 1 | 1998 | 1577 | 0.030 |
Why?
|
| Parathyroid Glands | 1 | 2013 | 509 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 905 | 0.020 |
Why?
|
| Binding Sites | 1 | 2000 | 6114 | 0.020 |
Why?
|
| Diuretics | 1 | 2013 | 592 | 0.020 |
Why?
|
| Hyperaldosteronism | 1 | 2013 | 240 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 1518 | 0.020 |
Why?
|
| Aortic Valve | 2 | 1997 | 1922 | 0.020 |
Why?
|
| Hormones | 1 | 2014 | 889 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 7939 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 1996 | 1151 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2017 | 1609 | 0.020 |
Why?
|
| Time Factors | 3 | 2020 | 40075 | 0.020 |
Why?
|
| Coronary Vessels | 2 | 1997 | 3107 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7799 | 0.020 |
Why?
|
| Epigenomics | 1 | 2014 | 903 | 0.020 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2011 | 544 | 0.020 |
Why?
|
| Genetics, Medical | 1 | 2010 | 338 | 0.020 |
Why?
|
| Diabetes Mellitus | 2 | 2016 | 5751 | 0.020 |
Why?
|
| Heart Rate | 1 | 1998 | 4091 | 0.020 |
Why?
|
| Mesocricetus | 2 | 1997 | 252 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 2503 | 0.020 |
Why?
|
| Streptozocin | 1 | 2006 | 196 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 2077 | 0.020 |
Why?
|
| Edema | 1 | 2010 | 789 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 1997 | 0.020 |
Why?
|
| Genetic Testing | 1 | 1998 | 3444 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 6171 | 0.020 |
Why?
|
| Osteopontin | 1 | 2006 | 296 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2006 | 569 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2023 | 53288 | 0.010 |
Why?
|
| Cricetinae | 2 | 1997 | 2472 | 0.010 |
Why?
|
| Cytokines | 1 | 2017 | 7322 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 11725 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2010 | 1065 | 0.010 |
Why?
|
| Protein Binding | 1 | 2014 | 9386 | 0.010 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2001 | 83 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2011 | 3748 | 0.010 |
Why?
|
| Linear Models | 1 | 2011 | 5952 | 0.010 |
Why?
|
| Indomethacin | 1 | 2001 | 332 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 25043 | 0.010 |
Why?
|
| Vitamin D | 1 | 2013 | 3223 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 689 | 0.010 |
Why?
|
| Maleates | 1 | 1997 | 17 | 0.010 |
Why?
|
| Diet, Atherogenic | 1 | 1997 | 95 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 12245 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 23338 | 0.010 |
Why?
|
| Enalapril | 1 | 1997 | 327 | 0.010 |
Why?
|
| Cardiovascular Agents | 1 | 2001 | 850 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1997 | 1792 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 12261 | 0.010 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2001 | 2282 | 0.010 |
Why?
|
| Aspirin | 1 | 2001 | 3282 | 0.010 |
Why?
|
Concepts
(254)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(27)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_